Shopping Cart
- Remove All
Your shopping cart is currently empty
Kinetensin acetate(103131-69-7 free base)
Catalog No. TP1116L
Alias Kinetensin (human) acetate
Kinetensin acetate(103131-69-7 free base) is isolated from pepsin-treated human plasma. Kinetensin acetate(103131-69-7 free base) is a neurotensin-like peptide.
Kinetensin acetate(103131-69-7 free base)
Catalog No. TP1116LAlias Kinetensin (human) acetate
Kinetensin acetate(103131-69-7 free base) is isolated from pepsin-treated human plasma. Kinetensin acetate(103131-69-7 free base) is a neurotensin-like peptide.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $96 | In Stock | |
| 5 mg | $188 | In Stock | |
| 10 mg | $307 | In Stock | |
| 25 mg | $540 | In Stock | |
| 50 mg | $779 | In Stock | |
| 100 mg | $1,090 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Kinetensin acetate(103131-69-7 free base)"
Meclinertant
SR 48692
T16034146362-70-1In house
Meclinertant (SR 48692) is a neurotensin receptor-1 (NT1) antagonist that blocks neurotensin-induced excitation and can be used to study neurological disorders.
- $78
Size
QTY
(±)-AC 7954 hydrochloride
T22476477313-09-0
(±)-AC 7954 hydrochloride is a urotensin-II (UT) receptor activator.
- $82
Size
QTY
SB-657510
T12848474960-44-6
SB-657510 is a urotensin II (UII) receptor (UT) antagonist. The Ki values of UT for human, monkey, cat, rat and mouse were 61, 17, 30, 65 and 56 nM, respectively. SB-657510 plays an anti-inflammatory role by inhibiting UII-induced inflammatory mediators, such as adhesion molecules, in human vascular endothelial cells and upregulation of cytokines and tissue factors. SB 657510 has a therapeutic effect on diabetes-related atherosclerotic disease in diabetic mouse models.
- $75
Size
QTY
SB-657510
T12848474960-44-6
SB-657510 is a urotensin II (UII) receptor (UT) antagonist. The Ki values of UT for human, monkey, cat, rat and mouse were 61, 17, 30, 65 and 56 nM, respectively. SB-657510 plays an anti-inflammatory role by inhibiting UII-induced inflammatory mediators, such as adhesion molecules, in human vascular endothelial cells and upregulation of cytokines and tissue factors. SB 657510 has a therapeutic effect on diabetes-related atherosclerotic disease in diabetic mouse models.
- $75
Size
QTY
SB 611812
T23323345892-71-9
SB 611812 is an antagonist of urotensin-II (UT) and can be used in studies about the treatment of cardiovascular disease.
- $38
Size
QTY
[Lys8, Lys9]-Neurotensin (8-13) acetate
T38807L
[Lys8, Lys9]-Neurotensin (8-13) acetate, a Neurotensin analog, exerts its analgesic effects through activation of the G protein-coupled receptors NTS1 and NTS2, with Ki values of 0.33 nM and 0.95 nM for hNTS1 and hNTS2 receptors, respectively[1].
- $89
Size
QTY
[Lys8, Lys9]-Neurotensin (8-13) acetate
T38807L
[Lys8, Lys9]-Neurotensin (8-13) acetate, a Neurotensin analog, exerts its analgesic effects through activation of the G protein-coupled receptors NTS1 and NTS2, with Ki values of 0.33 nM and 0.95 nM for hNTS1 and hNTS2 receptors, respectively[1].
- $89
Size
QTY
AF38469
AF-38469
TQ00861531634-31-7
AF38469 is a new, specific and orally bioavailable Sortilin inhibitor (IC50: 330 nM).
- $107
Size
QTY
Substance P 1-9 aceate
TP1819L
Substance P 1-9 aceate is nonapeptide, which decreases the inactivation of substance P by the guinea-pig ileum and urinary bladder.
- $59
Size
QTY
Substance P 1-9 aceate
TP1819L
Substance P 1-9 aceate is nonapeptide, which decreases the inactivation of substance P by the guinea-pig ileum and urinary bladder.
- $59
Size
QTY
Select Batch
Purity:100%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Kinetensin acetate(103131-69-7 free base) is isolated from pepsin-treated human plasma. Kinetensin acetate(103131-69-7 free base) is a neurotensin-like peptide. |
| In vitro | The peptide kinetensin isolated from pepsin-treated human plasma induces a dose-dependent release of histamine when exposed to rat peritoneal mast cells. The threshold concentration is around 1 μM, the ED50 is 10 μM, and the optimal concentration of between 100 to 1000 μM released 80% of the total histamine. Kinetensin is 10 to 100 times less potent than neurotensin and equipotent with the opioid peptide dynorphin. The histamine release is clearly temperature-dependent, with no release occurring at 0 or 45 °C and with an optimum around 37 °C. The histamine release is significantly reduced in the absence of extracellular calcium[2]. |
| In vivo | Kinetensin also induces a dose-dependent increase in vascular permeability when injected intradermally into rats[2]. |
| Alias | Kinetensin (human) acetate |
| Molecular Weight | 1232.45 |
| Formula | C58H89N17O13 |
Storage & Solubility Information
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
| Solubility Information | DMSO: 10 mM | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Kinetensin acetate(103131-69-7 free base) | purchase Kinetensin acetate(103131-69-7 free base) | Kinetensin acetate(103131-69-7 free base) cost | order Kinetensin acetate(103131-69-7 free base) | Kinetensin acetate(103131-69-7 free base) chemical structure | Kinetensin acetate(103131-69-7 free base) in vivo | Kinetensin acetate(103131-69-7 free base) in vitro | Kinetensin acetate(103131-69-7 free base) formula | Kinetensin acetate(103131-69-7 free base) molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.